Faculty Collaboration Database

2010 report from the Center for International Blood and Marrow Transplant Research (CIBMTR): current uses and outcomes of hematopoietic cell transplants for blood and bone marrow disorders. Clin Transpl 2010:87-105

Date

01/01/2010

Pubmed ID

21696033

Scopus ID

2-s2.0-79960030746 (requires institutional sign-in at Scopus site)   140 Citations

Abstract

These data indicate increasing use of HCT for persons with blood and bone marrow disorders. Recent trends include increasing use of alternative donors including HLA-matched unrelated persons and of HLA-matched umbilical cord blood cells, increasing use of blood cell rather than bone marrow grafts and increasing use of reduced-intensity pretransplant conditioning regimens. Many of these shifts are driven by logistical considerations like the need for donors in persons without an HLA-identical sibling or expanding access to allotransplants to older patients. In other instances, like the shift from bone marrow to blood cell grafts or from conventional to reduced-intensity pretransplant conditioning regimens few randomized clinical trials have been reported to justify these shifts. More data are needed to critically-assess the impact of these changes.

Author List

Pasquini MC, Wang Z, Horowitz MM, Gale RP

Authors

Mary M. Horowitz MD, MS Professor in the Medicine department at Medical College of Wisconsin
Marcelo C. Pasquini MD, MS Professor in the Medicine department at Medical College of Wisconsin

MESH terms used to index this publication - Major topics in bold

Academies and Institutes
Bone Marrow Diseases
Cooperative Behavior
Graft Rejection
Graft Survival
Hematologic Diseases
Hematopoietic Stem Cell Transplantation
Humans
International Cooperation
Registries
Risk Assessment
Risk Factors
Survival Analysis
Survival Rate
Time Factors
Treatment Outcome